| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 9
| Issue : 1 | Page : 71-81 |
|
|
The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades
Gabriela Rocha Lauretti
Department of Biomechanics, Medicine and Rehabilitation of Locomotor Members, Teaching Hospital, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
Correspondence Address:
Prof. Gabriela Rocha Lauretti
Rua Maestro Joaquim Rangel, 644, CEP 14025-610 Ribeirão Preto, São Paulo
Brazil
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1658-354X.146319
|
|
|
Since the first clinical application of analgesia following spinal anticholinesterase by 1940's, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 μg, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
